There are currently 2025 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
NCT05943210
Recruiting
This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/24/2025
Locations: The University of Chicago, Chicago, Illinois
Conditions: Rectal Cancer
Register for Updates
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
NCT06392841
Recruiting
This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, PALB2 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation
Register for Updates
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685
Recruiting
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: The University of Illinois at Chicago, Chicago, Illinois
Conditions: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Register for Updates
SuperSaturated Oxygen Comprehensive Observational Registry
NCT06438315
Recruiting
The SuperSaturated Oxygen Comprehensive Observational Registry (SSCORE) registry, a prospectively designed observational study, aims to evaluate the clinical utility and effectiveness of SuperSaturated Oxygen (SSO2) Therapy versus percutaneous coronary intervention (PCI) alone among patients with anterior acute myocardial infarction (AMI) in routine clinical practice. The goal is to collect real-world data from patients treated with SSO2 Therapy to determine its impact on the overall heart failu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: STEMI - ST Elevation Myocardial Infarction, AMI
Register for Updates
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868
Recruiting
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Local Institution - 0278, Chicago, Illinois +1 locations
Conditions: Breast Neoplasms
Register for Updates
An Intervention to Reduce Sedentary Behavior for Black Adults With Chronic Kidney Disease
NCT06754280
Recruiting
RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized to an attention control condition that provides CKD-related education not related to sedentary behavior. All participants will be followed for 12 weeks.
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
07/24/2025
Locations: UI Health/University of Illinois Chicago, Chicago, Illinois
Conditions: Chronic Kidney Disease(CKD)
Register for Updates
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
NCT05719714
Recruiting
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure
Register for Updates
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
NCT05479812
Recruiting
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Register for Updates
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
NCT05953337
Recruiting
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/23/2025
Locations: University of Illinois Hospital and Health Sciences System, Chicago, Illinois
Conditions: Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
Register for Updates
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Arthrosi Investigative Site (657), Chicago, Illinois
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Register for Updates
Aging and Task-specific Training to Reduce Falls
NCT07094659
Recruiting
The goal of this clinical trial is to examine the effects of a novel task-specific balance training for reducing environmental falls in community ambulatory older adults who are at-risk of falling. The main questions it aims to answer are: * Does task-specific balance training improve the ability to prevent falling when unexpected perturbations such as slips and trips occur, and/or improve balance control during self-initiated movements? * Does task-specific balance training reduce real-life fa... Read More
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
07/23/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Fall Prevention
Register for Updates
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
NCT06911632
Recruiting
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: University of Illinois Health, Chicago, Illinois
Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Register for Updates